A series of 7-aminothiadiazolylcephalosporins having a 1-(substituted)-1H-imidazo [4,5-b]pyridinium group at the C-3' position of the cephem nucleus were synthesized and evaluated
(CZOP)3), and cefoselis (CFSL)4), have potent activity against Gram-positive bacteria and Gram-negative bacteria including Pseudomonas aeruginosa, and are widely used for the treatment of bacterial infections. However, their activity against methicillin-resistant Staphylococcus aureus (MRSA) is not sufficient for clinical use. MRSA as well as Pseudomonas aeruginosa is a nosocomial pathogen associated with serious infections and considerable mortality. Also, the incidence of mixed infection by MRSA and Pseudomonas aeruginosa has been increasing5), and antibacterial agents having high activity against these two pathogens are needed. We attempted to enhance the anti-MRSA activity of C-3' quaternary ammonium cephalosporins while retaining potent activity against Gram-negative bacteria including Pseudomonas aeruginosa. It was a challenge to find such a parenteral C-3' quaternary ammonium cephalosporin with potent activity against MRSA and sufficient water solubility for administration because quaternary ammonium cephems possessing anti-MRSA activity may not be sufficiently soluble in water due to their zwitterionic structure.
In the course of searching for novel C3'-quaternary [4,5-b ]-pyridinium-4-yl]methyl-3-cephem-4-carboxylate (1) (Fig.  1 ), which showed potent activity against MRSA and Pseudomonas aeruginosa. We further investigated the influence of various substitutions (R1, R2) on both antibacterial activity and water solubility. Eventually, we discovered a promising compound for further evaluation, acetamido]-3-[1-(3-methylaminopropyl)-1H-imidazo [4,5-b] pyridinium-4-yl]methyl-3-cephem-4-carboxylate sulfate (S-3578), which displayed excellent activities against MRSA as well as Pseudomonas aeruginosa, and good water solubility (>100mg/ml, at pH 2-7). Herein, we describe the synthesis and structure-activity relationships alkoxyiminoacetamido]-3-[1-(substituted)-1H-imidazo [4,5-b] pyridinium-4-yl]methyl-3-cephem-4-carboxylates.
2(Z)-ethoxyiminoacetamido]-3-[1H-imidazo

Synthesis
Cephalosporin derivatives bearing the 1-(substituted)-1H-imidazo [4,5-b] pyridine at the C-3' position were synthesized as shown in Scheme 1. The cephem nucleus6) using phosphorus oxychloride or phenyl phosphorodichloridate in the presence of Nmethylmorpholine. The C-3 chloromethyl cephalosporin intermediate (IIIa-f) was treated with sodium bromide or sodium iodide to give the corresponding bromide or iodide, which was displaced by the corresponding 1-(substituted)-1H-imidazo [4,5-b] pyridine (3-5, 7, 8, 10-17, 28-34, 43, 44, 46, 48, 49, 51, 52, 55 or 57) to afford a mixture of IVa-f and a regioisomer (Va-f), which was treated with an AlCl3-anisole, TiCl4-anisole or H2SO4-HCO2H system. Purification on reversed phase (HP-20) column chromatography yielded cephalosporin derivatives (1, .
The methods of synthesizing 1-(substituted)-1H-imidazo [4,5-b] pyridine are shown in Schemes 2-9. 1-tertButoxycarbonyl-1H-imidazo [4,5-b] pyridine (3) was prepared by treatment of commercially available 1H-imidazo [4,5-b] pyridine (2) with di-tert-butyl dicarbonate (Boc2O) (Scheme 2). To introduce an alkyl group onto the 1-position of 1H-imidazo [4,5-b] pyridine, three methods (Method A-C in Scheme 3) were employed with reference to KHANNA'S procedure10). In Method A, compounds [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] were prepared by a reaction of 1H-imidazo [4,5-b] pyridine (2) with the corresponding alkyl halide or methanesulfonate (4'-17') in the presence of a base (NaH or Cs2CO3). In this method, an undesired regioisomer, 3-(substituted)-3H-imidazo [4,5-b] pyridine was also produced. In Method B, compounds 11, 12, [28] [29] [30] [31] [32] [33] [34] Compound 57 was prepared by the method shown in Scheme 9. Esterification of 45 was achieved by using diazomethane followed by treatment with 28% NH4OH to afford compound 57.
Results and Discussion Table 1 shows the antibacterial activities of cephems bearing the 1H-imidazo [4,5-b] pyridine derivative, and the reference compounds CZOP, CFSL and vancomycin (VCM). MICs were determined by the standard serial twofold dilution method using Mueller-Hinton medium.
Compound 1 showed potent antibacterial activities against Gram-positive bacteria including MRSA and Gramnegative bacteria including Pseudomonas aeruginosa. In particular, the anti-MRSA activity of 1 was superior to that of the reference compounds CZOP and CFSL but inferior to that of VCM. The introduction of a methyl group at the 1-position of imidazopyridine (58) enhanced the antibacterial activity against MRSA and Pseudomonas aeruginosa. Lengthening of the methylene chain (59-61) did not further improve the anti-MRSA activity, but decreased potency against Pseudomonas aeruginosa compared with 58. Compounds 62-64 containing functional groups, such as a difluoromethyl (62), a hydroxy ethyl (63) or a carbamoylmethyl (64) group, were less active than 58 against both MRSA and Pseudomonas aeruginosa. However, compound 65 having an aminoethyl group showed the same activity against MRSA and Pseudomonas aeruginosa as that of 58. Among these compounds (1, (58) (59) (60) (61) (62) (63) (64) (65) , 58 and 65 were the most active against MRSA and Pseudomonas aeruginosa. Although 58 had low water solubility (solubility of 58; <10mg/ml), compound 65 had good water solubility due to salt formation (solubility of 65 hydrochloride; >100mg/ml). These findings led us to explore a variety of carbon lengths Pseudomonas aeruginosa, 65 and 68 were more active than 69. Among compounds 65-69, the 3-aminopropyl derivative 68 showed the most potent activity against MRSA and Pseudomonas aeruginosa. Therefore, our attention was next focused on the preparation of cephalosporin derivatives bearing a variety of 1-(3-aminopropyl)-1H-imidazo [4,5-b] pyridinium analogs. We explored the effects of the substituent of the 3-aminopropyl moiety of compound 68. Table 3 shows the activities of cephalosporin derivatives bearing a variety of 1-(3-aminopropyl)-1H-imidazo [4,5- b]pyridinium analogs. Further improvement of antibacterial S. a., Staphylococcus aureus SMITH; MRSA 1, S aureus SR3626; MRSA 2, S. aureus SR3637; E. c., Escherichia coli NIHJ JC-2; P. a. 1, Pseudomonas aeruginosa SR24; P. a. 2, P. aeruginosa SR5393 CZOP, cefozopran; CFSL, cefoselis; VCM, vancomycin activity against MRSA and Pseudomonas aeruginosa was not observed by modification of compound 68. The introduction of a methyl group (70) or a hydroxyethyl group (74) on the primary amine and a methyl group (77, 78) or a cyclopropyl group (79) on a spacer carbon chain of 3-aminopropyl derivative 68 had no effect on anti-MRSA activity compared to that of compound 68. Compounds 82-85 having a cyclic amino group or compound 76 having a guanidyl group instead of an amino group also showed the same activity as compound 68 against MRSA.
However, introduction of dimethyl groups (71) or a larger substituent than the methyl group, such as an ethyl (72) or a cyclopropyl (73) group on the primary amine, and an electron-withdrawing group such as a trifluoromethyl (80) or a carbamoylmethyl group (81) on the spacer carbon chain diminished activities against MRSA. Regarding the antibacterial activity against Pseudomonas aeruginosa, the activities of all compounds were inferior to that of compound 68.
While optimizing the C-3 substituent, we investigated the substituent effect of the C-7 oxime moiety. Some examples are shown in Table 4 . In analogs of compound 70, the ethoxyimino moiety was modified. The isopropyl analog 87 had the same activity as 70 against MRSA and Among the novel cephalosporin derivatives having a 1-(substituted)-1H-imidazo [4,5-b] pyridinium group at C-3', 68 had the highest activity against MRSA and Pseudomonas aeruginosa. However, subsequent evaluation of 68 revealed that its mouse acute toxicity (iv.) was relatively strong. The other analogs were also evaluated for mouse acute toxicity. And compounds 70 and 74 were selected based primarily on a favorable combination of antibacterial activity and mouse acute toxicity. Ultimately, on the basis of physicochemical property, we selected crystalline 70 sulfate, not amorphous 74, as a promising candidate for further evaluation and designated as S-3578.
Experimental
IR spectra were taken on a JASCO IR-700 spectrometer. 1 H-NMR spectra were recorded on a Varian Gemini-300 see footnote in Table 1 .
abbreviations: see footnote in Table 1 . 
To a solution of 1H-imidazo [4,5-b] pyridine (2) (775mg, 6.5mmol) in DMF (8ml) was added di-tert-butyl Bicarbonate (1.65ml, 7.15mmol ) under cooling on an icewater bath, and the mixture was allowed to stand overnight at room temperature. After evaporation of the solvent, the residue was purified by silica gel column chromatography to give the title compound 3 (1.16g, 81% yield); 1H-NMR [4,5-b] pyridine (12) (Method A) To a solution of 1H-imidazo [4,5-b] pyridine (2) (5.15g, 34.8mmol) in DMF (35ml) was added 60% NaH (1.53g, 38.2mmol) under cooling on an ice-water bath, and the mixture was stirred at room temperature for 15 minutes. To the mixture was added a solution of 3-tertbutoxycarbonyl-methylaminopropyl methanesulfonate (12') (10.2g, 38.2mmol) in DMF (20ml) . The reaction mixture solvent, the residue was chromatographed on silica gel column. The fraction eluted with EtOAc was concentrated to give a regioisomer, 3-[3-(tert-butoxycarbonyl-methylamino)-propyl]-3H-imidazo [4,5-b] To a mixture of compound 39 (7.89g, 28mmol ) and triethyl orthoformate (46.6ml) was added p-toluenesulfonic for 40 minutes. The reaction mixture was concentrated in vacuo and to the residue was added EtOAc and saturated NaHCO3. The organic layer was washed with saturated NaHCO3 and brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by silicagel column chromatography to give compound 12 (7.17g, 88% from 38) with properties identical to the product reported above.
The other 1-(substituted)-imidazo [4,5-b] pyridines (4-11, 13-17, 28-34, 43-45) were prepared by procedures (Method A-C) similar to those described for the preparation of 12.
1-Methyl-1H-imidao [4,5-b] pyridine (4) (Method A) Compound 4 was obtained in 70% yield from 2 using iodide 4' and NaH as a base; 1H-NMR (1H, dd, J=1. 5, 8.1Hz), 8.11 (1H, s), 8.50 (1H, dd, J=1.5, 5.1Hz ).
1-Ethyl-1H-imidao [4,5-b] 1-Difluoromethyl-1H-imidazo [4,5-b] pyridine (7) (Method A) Compound 7 was obtained in 48% yield from 2 using chloride 7' and Cs2CO3 as a base; 1H-NMR 1-Ethoxycarbonylmethy-1H-imidazo [4,5-b] pyridine (9) (Method A) Compound 9 was obtained in 53% yield from 2 using iodide 9' and NaH as a base; 1H-NMR (Method B) Compound 11, which had properties identical to the product reported from Method A, was obtained in 80% yield from 18 using aldehyde 19.
1-(4-tert-Butoxycarbonylamino-butyl)-1H-imidazo [4,5-b] pyridine (13) (Method A) Compound 13 was obtained in 22% yield from 2 using methanesulfonate 13' and NaH as a base; 1H- 1-(1-tert-Butoxycarbonyl-azetidin-3-ylmethyl)-1H-imidazo [4,5-b] pyridine (14) (Method A) Compound 14 was obtained in 22% yield from 2 using methanesulfonate 14' and NaH as a base; 1H- 
1-[(3S)-1-tert-Butoxycarbonyl-pyrrolidin-3-yl]-1H-
imidazo [4,5-b] pyridine (16) (Method A) Compound 16 was obtained in 16% yield from 2 using methanesulfonate 16' and Cs2CO3 as a base. [4,5-b] 1-Cyclopropylmethyl-1H-imidazo [4,5-b] [4,5-b] pyridine (32) (Method B) Compound 32 was obtained from 18 in 79% yield using aldehyde 25.
1-(1-tert-Butoxycarbonyl-piperidin-4-yl)-1H-imidazo-
1-[(3S)-3-tert-Butoxycarbonylamino-butyl]-1H-imidazo-
1-[2-(1-tert-Butoxycarbonylamino-cyclopropyl)-ethyl]-
1H-imidazo [4,5-b] 
1-[(2S)-2-tert-Butoxycarbonylamino-butyl]-1H-imidazo-
1-[(3S)-3-tert-Butoxycarbonylamino-3-carboxy-propyl]-
1H imidazo [4,5-b] pyridine (45) (Method C) Compound 45 was obtained from diaminopyridine 35 using aldehyde 38 in 68% yield; 1H-(1H, m), 4.34 (2H, t, J=6.6Hz), 7.28 (1H, dd, J=4.5, 7.8Hz), 7.37 (1H, d, J=7.8Hz), 8.08 (1H, d, J=6.9Hz), 8.41 (1H, s), 8.42 (1H. d, J=6.9Hz ).
1-Carbamoylmethyl-1H-imidazo [4,5-b] pyridine (46) To a solution of compound 9 in EtOH (20ml) was added 28% NH4OH and the reaction mixture was stirred at room temperature for 30 minutes. After evaporation of the solvent, the residue was purified by HP-20 resin chromatography to afford compound 46 (1.41g [4,5-b] pyridine (49) To compound 6 (660mg, 3.25mmol) was added cyclopropyl amine (2.4ml) and this was stirred at room temperature for 2 hours. To the reaction mixture was added cyclopropylamine (1.2ml) and the reaction mixture was stirred overnight at room temperature then refluxed for 3 hours. After evaporation, the residue was dissolved in DMF (6ml) then Boc2O (0.85ml) was added to the solution. After stirring the reaction at room temperature for 2 hours, 4-dimetylaminopyridine (82mg) was added and stirring was continued overnight. After evaporation, the residue was chromatographed on a silica gel column to give compound m), 0.74 (2H, m), 1.44 (9H, s), 2.15 (2H, m), 2.47 (1H, m), 3.30 (2H, t, J=6.6Hz), 4.22 (2H, t, J=7.2Hz), 7.25 (1H, dd, J=5.01, 8.1Hz), 7.75 (1H, dd, J=1.8, 7.8Hz), 8.21 (1H, s), 8.59 (1H, dd, J=1.8, 4.5Hz ). [4,5-b] pyridine (50) To a solution of compound 11 (1.14g, 4.13mmol) in DMF (6ml) was added 60% NaH (250mg, 6.2mmol) and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added a solution of (2-bromo- 
1-[3-(tert-Butoxycarbonyl-cyclopropyl-amino)-propyl]-1H-imidazo
1-[3-[tert-Butoxycarbonyl-(2-triethylsilanyloxy-ethyl)-amino]-propyl]-1H-imidazo
To a solution of compound 51 (0.97g, 3.02mmol) of THF (15ml) was added tri-n-butylphosphine (1.13ml, 4.53mmol), di-tert-butyl iminodicarboxylate (0.995g, 4.53mmol) and 1,1'-(azodicarbonyl)dipiperidine (1.15g, 4.53mmol) under cooling on an ice-water bath, stirred for 15 minutes, and stirred at room temperature for 3 hours.
Next, tri-n-butylphosphine (0.37ml, 1.5mmol), di-tertbutyl iminodicarboxylate (0.33g, 1.5mmol) and 1,1'-(azodicarbonyl)dipiperidine (0.38g, 1.5mmol) were added to the reaction mixture and this was stirred for 2 hours. After filtration of insoluble material, EtOAc was added to the filtrate followed by washing with H2O, dried over MgSO4, filtration and concentration under reduced pressure. The residue was chromatographed on a silica gel column to give compound 52 (1.14g, 72%); 1H-NMR [4,5-b] pyridine (55) To a solution of compound 53 (747mg, 13mmol) in DMF (10ml) was added 1H pyrazole-1-[N,N'-bis(tertbutoxycarbonyl)carboxamidine (54) (978mg, 14.3mmol) and this was stirred at room temperature overnight. After addition of EtOAc and water, the organic phase was washed with water and brine, dried over MgSO4, and filtered off. m), 5.45 (1H, d, J=7.5Hz), 7.25 (1H, dd, J=4.8, 8.1Hz), 7.75 (1H, dd, J=1.5, 8.1Hz), 8.22 (1H, s), 8.59 (1H, dd, J=1.5, 4.5Hz ).
1-[(3S)-3-tert-Butoxycarbonylamino-3-carbamoyl-
propyl]-1H-imidazo [4,5-b] pyridine (57) To a solution of compound 56 (4.5g, 13.5mmol) was added 28% NH4OH (10ml) with stirring at room temperature for 4 hours then the mixture was left standing To a suspension of compound II (102g, 252mmol) in EtOAc (1 liter) was added N-methylmolpholine (28ml, (80.67g, 252mmol) and phosphorus oxychloride (24ml, 264mmol) at the same temperature, followed by dropwise addition of N-methylmolpholine (86.7ml, 792mmol) at the organic phase was washed successively with aqueous NaHCO3 and brine, dried over MgSO4 and filtered. The filtrate was concentrated in vacuo to give crude IIIb (188g, 92% purity, 82% yield).
To a solution of imidazopyridine 12 (28.9g, 99.8mmol) in DMF (92ml) was added the chloromethyl derivative IIIb (81.2g, 99.8mmol) and NaBr (20.5g, 199mmol) . The mixture of 2-propanol (8.5 liters) and acetone (1 liter). The precipitate was collected by filtration and dissolved in H2O (300ml). The solution was chromatographed on HP-20 resin. The target product was eluted with 2% MeCN/0.001N H2SO4. The solution containing the target product was adjusted to pH 4.5 by addition of poly (4-vinylpyridine) and filtered. The filtrate was concentrated and lyophilized to give 70 sulfate (crude S-3578) (31g, 42% yield from IIIb); IR (KBr) cm , 1634 , 1464 Anal Calcd for C24H28N10O5S2 Found: C 39.22, H 5.18, N 19.22, S 10.88. To a solution of the described crude S-3578 (70 sulfate) 4.0g in H2O (12ml) was added 10N H2SO4 (0.65ml) and temperature for a week, the crystallized solid was filtered and dried under reduced pressure (15mmHg at room temperature for 1.5 hour) to afford pure S-3578 (1.67g, (3H, t, J=7.5Hz), 2.42 (2H, m), 2.74 (3H, s), 3.16 (2H, t like, J=8.1Hz), 3.34 and 3.64 (2H, ABq, J=18.3Hz), 4.33 (2H, q, J=7.5Hz), 4.65 (2H, t like, J=7.5Hz), 5.25 (1H, d, J=4.8Hz), 5.71 and 5.94 (2H, ABq, J=15Hz), 5.87 (1H, d, J=4.8Hz), 7.89 (1H, dd, J=6.6, 8.1Hz), 8.82 (1H, d, J=8.1Hz), 8.86 (1H, d, J=6.6Hz), 8.89 (1H, s) ; Anal 16.98, S 11.66. Found: C 34.67, H 5.30, N 17.16, S 11.72 .
The other cephalosporins (1, (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) (71) (72) (73) (74) (75) (76) (77) (78) (79) (80) (81) (82) (83) (84) (85) (86) (87) (88) (89) ) were prepared by a procedure similar to that described for the preparation of S-3578 (70 sulfate). 
